Not only are patients with prediabetes benefiting from Omada Health’s Prevent program, Omada benefits as well by learning from the enrolled patients about how to better serve the Medicaid population, Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.
Not only are patients with prediabetes benefiting from Omada Health’s Prevent program, Omada benefits as well by learning from the enrolled patients about how to better serve the Medicaid population, Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.
Transcript (slightly modified)
The Omada Health Prevent program is offered in 2 languages and is targeted towards low-income populations. What is the importance of having these options available?
Well I’ll touch on the second point that you made, low-income individuals, first. We call them the safety net of patients and it’s because those patients tend to actually bounce around from an insurance perspective between Medicaid, the new individual exchanges, and then being uninsured. And, the long story short is it would be unethical of us to kind of discover this new delivery mechanism for clinical psychology and not make it available to everybody.
And, I worked for a long time in the pharmaceutical industry before I joined Omada and 1 very good thing about the pharmaceutical industry is that they do provide drug to underserved patients at lower prices. Obviously, that has helped them grow as an industry but that’s a very ethical approach and it’s one that both government and the American population seems to be in line with, that in some ways those who are more able to pay are kind of cross subsidizing our ability to work with underserved patients.
And, there’s another really interesting dynamic here, which is that uninsured Medicaid safety net patients, a lot of them work for employers, not surprisingly. And so, Omada’s work with self-insured employers to make their employees healthier often times teaches us a lot of lessons about how to treat the uninsured population. There are a lot of employers out there with low-income, young, overweight, English-as-a-second-language populations and so as we work with those employers on their lower paid staff, we’re learning about how to treat Medicaid patients at the same time and vice versa. So, it’s a synergistic model to treat all of these groups across the spectrum.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More